Becker's Healthcare March 27, 2023
SR One, a life sciences investment firm spun out of biotech giant GlaxoSmithKline, raised $600 million to close its second venture fund.
The fund surpassed its original target of $500 million. With this fund, SR One will continue on its mission to target companies working to close gaps in treatment, according to a March 27 SR One news release.
Since spinning out of GSK in 2020, SR One has $1.5 billion under management.
“We received an incredible response to the fund and are...
Today's Sponsors
Today's Sponsor